Objectives: To identify a clinically reliable index of thyrotoxic periodic paralysis (TPP), a life-threatening emergency with unique and effective therapies.
H ypokalemic paralysis (HP) is a potentially reversible metabolic emergency characterized by acute muscle weakness and severe hypokalemia (1, 2) . In general, HP can be divided into two groups: hypokalemic periodic paralysis (HPP), due to an acute shift of potassium (K ϩ ) into cells, and non-HPP, where there is a large total body deficit of K ϩ (3) . Within the HPP subgroup, the most common causes are thyrotoxic periodic paralysis (TPP) in Asia and familial periodic paralysis in Western countries (4, 5) . Within the non-HPP subgroup, excessive vomiting, profound diarrhea, defective intestinal absorption, diuretic use, primary hyperaldosteronism, chronic pure licorice ingestion, Bartter's syndrome/Gitelman's syndrome, toluene abuse, and renal tubular acidosis are common etiologies (6) .
The incidence of TPP is about 0.1-0.2% among Caucasian hyperthyroid patients and about 1.9 -8.8% among Asian hyperthyroid patients (4) . Although the incidence of TPP is relatively high in the Asian population, TPP is no longer confined to certain geographic areas due to globalization and immigration (7) . In addition, TPP has been increasingly reported in many other ethnic groups (8, 9) . The neuromuscular presentations of TPP and non-TPP are often indistinguishable. Despite the linkage to hyperthyroidism, the signs and symptoms in TPP may be subtle and attacks of periodic paralysis may precede overt signs or symptoms of hyperthyroidism. This makes early diagnosis of TPP very difficult unless results of thyroid function tests are available in the emergency department (ED). Therefore, a quick, reliable, and easily performed test is needed to differentiate patients with TPP from those with non-TPP. Otherwise, TPP may go unrecognized or be misdiagnosed as non-TPP, leading to serious management errors (10) , such as iatrogenic rebound hyperkalemia on recovery due to overly vigorous KCl supplementation for a presumed total K ϩ deficit.
In embarking on this study, we hypothesized that the analysis of blood and urine electrolytes and acid-base status may help differentiate patients with TPP from those with non-TPP in the ED and tried to find a rapid and reliable indicator of TPP. The results to be reported indicate that hypercalciuria and hypophosphaturia are unique features of TPP and that the spot urine calcium to phosphate ratio (Ca/P) is even more sensitive in differentiating TPP from non-TPP.
PATIENTS AND METHODS
Study Subjects. The study protocol was approved by the Ethics Committee on Human Studies at Tri-Service General Hospital, National Defense Medical Center, in Taiwan, ROC. The subjects were given a detailed description of the study before they provided informed consent. From July 2002 to June 2005, we prospectively studied every patient who presented to the ED of an urban academic medical center with HP. HP was defined as acute muscle weakness with an inability to ambulate and plasma K ϩ Ͻ3.0 mEq/L at the time of presentation. The paralysis tended to involve the muscles of the extremities and limb girdles. All patients received a standard 12-lead electrocardiogram. Blood pressure was recorded every 3 mins, and electrocardiogram monitoring was recorded continuously on an electrocardiographic oscilloscope (Hewlett Packard, Boeblingen, Germany). All of the HP patients received intravenous potassium chloride (KCl) infusion in half-normal saline at a rate of 10 mEq/hr until muscle strength had recovered. TPP was diagnosed in patients with hypokalemia, paralysis, and low K ϩ excretion in the presence of hyperthyroidism. TPP was subsequently confirmed by thyroid function tests. Non-TPP was defined as the presence of hypokalemia and paralysis in the absence of hyperthyroidism. Thirty age and gender-matched, untreated thyrotoxic patients without episodic attacks of muscle weakness or paralysis were selected as the thyrotoxic control group.
Procedures. An arterial blood sample was collected in all the patients; venous blood samples were also collected through indwelling catheters. A spot urine was collected before initiation of therapy by self-void if possible or with a Foley catheter if the patient was unable to urinate. To avoid the possibility of obtaining mixed urine that preceded the onset of attack, urine in the bladder on presentation was discarded and a second-void urine specimen was collected for analysis within the first hour (3) . For the thyrotoxic control group, blood and spot urine were collected without water deprivation when patients visited outpatient clinics.
Measurements. Arterial blood gases were measured with an ABL 510 (Radiometer, Copenhagen, Denmark). Biochemical values including serum and urine creatinine, urea nitrogen, albumin, total calcium, ionized calcium, inorganic phosphate, magnesium, sodium (Na ϩ ), K ϩ , and chloride were determined by automated methods (AU 5000 chemistry analyzer; Olympus, Tokyo, Japan). Plasma and urine osmolality were measured by freezing point depression (Advanced Instruments, Needham Heights, MA). Plasma total triiodothyronine, free thyroxine, and thyroidstimulating hormone concentrations were measured by commercial kits (Diagnostic Products Corporation, Los Angeles, CA).
Calculations. The TTKG, an index of renal K ϩ excretion, was calculated as previously described: (urine/plasma [K ϩ ])/(urine/plasma osmolality) (11, 12) . Urine phosphate to creatinine ratio, an index of urinary phosphate excretion, and urine calcium to creatinine ratio, an index of urinary calcium excretion, are expressed in mg/mg (13) . Urine Ca/P is also expressed as mg/mg. Statistical Analysis. All results are expressed as mean Ϯ SD. We used one-way anal-ysis of covariance to compare the difference among three groups (control, TPP, and non-TPP) after adjustment for age and gender. The Bonferroni multiple comparisons procedure was applied to evaluate the difference between subgroups (such as control vs. TPP, control vs. non-TPP, and TPP vs. non-TPP). The Kruskal-Wallis test was used when the variables among three groups were not normally distributed. Differences were considered significant at p Ͻ .05. A conventional receiver operating characteristic curve was used to determine the sensitivities and specificities at different cutoff points for the diagnostic criteria of patients with TPP and non-TPP. Receiver operating characteristic curve analysis was performed using GraphPad Prism software version 4.0.
RESULTS

Patient Characteristics in Control,
TPP, and Non-TPP Groups. Fifty-three patients with HP were identified during this period. They had a severe degree of hypokalemia with plasma K ϩ concentration ranging from 1.5 to 2.4 mEq/L. The male to female ratio was 43:10; their age ranged from 18 to 80 yrs. Of the 53 HP patients, 29 had TPP and 24 had non-TPP ( Table 1 ). The male to female ratio in TPP was 26:3 and 16:8 in non-TPP. Age ranged from 19 to 48 yrs with mean age 28 in TPP and 18 to 80 yrs with mean age 42 in non-TPP. In the TPP group, the etiologies of hyperthyroidism were Graves' disease in 26, toxic nodular goiters in two, and subacute thyroiditis in one. Approximately 76% of TTP patients (22 of 29) were not known to have hyperthyroidism before the paralytic attack. Positive family history of hyperthyroidism was present in six TTP patients (21%). The etiologies in the non-TPP subgroup are shown in Table 1 . Sporadic periodic pa-ralysis (SPP), a unique subgroup of HPP, was diagnosed in patients with neither a family history of paralysis nor hyperthyroidism. The diagnosis of Gitelman's syndrome was based on the following criteria: hypokalemia and hypomagnesemia of renal origin, and hypocalciuria with urinary calcium/creatinine ratio Ͻ0.04 mg/mg (14) . The diagnosis of distal renal tubular acidosis was based on the findings of metabolic acidosis without an increase in the anion gap of plasma, a low rate of ammonium excretion (a positive urine net charge), and a urine pH Ͼ6 (15). Sjogren's syndrome was the cause of the distal renal tubular acidosis. The diagnosis of anorexia/bulimia nervosa met criteria of the Diagnostic and Statistical Manual of Mental Disorders (fourth edition). Cola-induced hypokalemia and paralysis were based on the positive history of daily excessive drinking of sugar and caffeine-containing cola, the exclusion of other identifiable causes of hypokalemia, and no recurrent hypokalemia after the cessation of cola ingestion (16) . Of note, six of TPP patients were not initially diagnosed to have hyperthyroidism on clinical grounds and seven (three SPP, two Gitelman's syndrome, one anorexia/ bulimia nervosa, and one excessive cola ingestion) of the non-TPP patients were initially diagnosed to have hyperthyroidism before the results of thyroid function tests.
Blood Biochemical Studies Among Control, TPP, and Non-TPP Groups. Thyroid function tests were all indicative of hyperthyroidism in the TPP and thyrotoxic control groups, whereas they were normal in non-TPP. In the thyrotoxic control group, plasma K ϩ concentration was nor- The number in parenthesis denotes a provisional clinical diagnosis of hyperthyroidism prior to the results of thyroid function tests. mal but phosphate concentration was significantly higher than normal subjects (data not shown). Compared with the thyrotoxic control group, the TPP group had a significant decrease in plasma K ϩ and phosphate concentrations ( Table 2 ).
There were no significant differences in plasma Na ϩ , chloride, HCO 3 Ϫ , pH, calcium, magnesium, urea nitrogen, or K ϩ concentration between TPP and non-TPP groups. There was a small but statistically significant lower plasma creatinine (0.7 Ϯ 0.2 vs. 1.0 Ϯ 0.3 mg/dL, p Ͻ .01) in the TPP vs. non-TPP groups. Although hypophosphatemia was usually present and significantly lower in TPP (2.0 Ϯ 0.5 vs. 2.5 Ϯ 0.7 mg/dL, p Ͻ .01), this finding was not unique to TPP because ten patients with non-TPP also presented with hypophosphatemia (one SPP, one Gitelman's syndrome, two distal renal tubular acidosis, three chronic alcoholism, one chronic licorice ingestion, one chronic glue-sniffing, and one excessive cola drinking).
Urine Electrolytes in Control, TPP, and Non-TPP Groups. Compared with the thyrotoxic control group, both urine K ϩ and phosphate excretion were significantly lower in TPP, suggesting there is an increased shift of both K ϩ and phosphate into cells in TPP. Both control and TPP groups have significantly higher urine calcium excretion rates compared with non-TPP. The spot urine Na ϩ , K ϩ (9 Ϯ 4 vs. 11 Ϯ 5 mEq/L, not significant), Cl Ϫ , creatinine concentrations and osmolality were not significantly different between TPP and non-TPP. TTKG (2.5 Ϯ 0.9 vs. 5.1 Ϯ 2.5, p Ͻ .001) was significantly lower in patients with TPP than non-TPP, but there was appreciable overlap. The urine calcium to creatinine ratio was significantly higher (0.25 Ϯ 0.12 vs. 0.08 Ϯ 0.07 mg/mg, p Ͻ .001) and urine phosphate to creatinine ratio significantly lower (0.08 Ϯ 0.05 vs. 0.31 Ϯ 0.23 mg/ mg, p Ͻ .001) in TPP, but there were also appreciable overlaps (Fig. 1) . In contrast, the urine Ca/P ratio separated TPP and non-TPP into two distinct clusters (4.1 Ϯ 2.3 vs. 0.5 Ϯ 0.6 mg/mg, p Ͻ .001) ( Fig.  1) . A receiver operating characteristic curve was constructed to determine the discriminatory power of urine Ca/P ratio for the diagnosis of TPP (Fig. 2) . The area under the receiver operating characteristic curve was 0.98, which showed that the urine Ca/P ratio was an excellent test for the diagnosis of TPP. The cutoff value of 1.7 mg/mg had the optimal sensitivity (100%) and specificity (96%) for TPP.
DISCUSSION
It has been reported that many patients with TPP do not have any symptoms of hyperthyroidism during an attack (4, 5, 17, 18) . Moreover, the measurement of thyroid hormones is unavailable in a reasonable time frame in most EDs. Therefore, other clinical clues are necessary to diagnose TTP. In our recent retrospective study, we observed distinct electrocardiogram features in patients with TPP, including rapid heart rate, high QRS voltage, and first-degree atrioventricular block (18) . In this prospective study, we found another useful clue, the rates of excretion of calcium and phosphate. To the best of our knowledge, there have been no studies comparing the urine calcium and phosphate excretion patterns in patients with TPP compared with those with non-TPP. The major findings in our patient population were that urinary phosphate excretion was significantly lower whereas urinary calcium excretion was significantly higher in patients with TPP.
Plasma phosphate concentration is maintained within the normal range through complex interactions between intestinal absorption, exchange with intracellular and bone, and renal tubular resorption. Consistent with previous reports in patients with hyperthyroidism (19, 20) , an elevated plasma phosphate concentration was frequently found in thyrotoxic controls. The mechanisms for this increased plasma phosphate concentration are primarily related to increased bone resorption, enhanced renal tubular resorption of phosphate by direct action of thyroid hormone, and suppression of PTH (20) . In contrast, TPP patients frequently present with hypophosphatemia accompanied by a dramatic decrease in urine phosphate excretion. The associated low urinary phosphate excretion may be due to the reduced filtration load of plasma phosphate and a renal response to hypophosphatemia. The spontaneous correction of hypophosphatemia without phosphate supplementation suggests that the hypophosphatemia of TPP, like the hypokalemia, is principally due to an intracellular shift of phosphate (1, 3) . However, the exact mechanism of hypophosphatemia in TPP remains to be clarified. Since hypokalemia and hypophos- phatemia are paired features of TPP, it is possible that these intracellular shifts occur through a common mechanism. Catecholamines and insulin are two wellknown hormones involved in increasing intracellular shifts of both ions (21, 22) . Since TPP is characterized by a hyperadrenergic and hyperinsulinemic state, the hypophosphatemia and hypokalemia may be the result of actions of these hormones (23, 24) . Perhaps the catecholamine and insulin effects overwhelm the renal reabsorptive effect of thyroid hormone during an acute TPP attack. Although hypophosphatemia is frequently found in patients with TPP, it can also be found in non-TPP patients with gastrointestinal and/or renal phosphate loss (25) .
Calcium metabolism is influenced by the hyperthyroid state (26) . Because intestinal calcium absorption is usually low or normal in hyperthyroidism (27) , high urine calcium excretion in the TPP group and thyrotoxic control likely originate from effects on bone and/or kidney (20, 28) . Stimulation of osteoclasts and bone turnover by the direct effects of thyroid hormone might lead to higher rates of calcium excretion (28, 29) . Renal factors potentially contributing to hypercalciuria in hyperthyroidism include increased glomerular filtration rate and diminished tubular resorption of calcium (20, 30) . In this study, TPP patients and the control group had a significant decrease in plasma creatinine concentration, indicating that their glomerular filtration rate is increased. A significant increase in fractional excretion of calcium adjusted by glomerular filtration rate and the lack of hypercalcemia in TPP patients and control group suggested that the basis for their hypercalciuria was primarily a diminished rate of renal resorption of calcium, but the mechanism for this effect was not clear. Perhaps reduced activity of the luminal calcium channel in the distal renal tubules directly by hyperthyroidism or indirectly by the suppressed PTH is involved (31) . Although hypercalciuria is a unique finding in patients with TPP, it did not by itself completely discriminate between TPP and non-TPP because a few patients with non-TPP also had a high urine calcium excretion rate.
Because there were diagnostic overlaps when using urine phosphate to creatinine ratio and urine calcium to creatinine ratio independently, we found that an index that magnifies the relative differences between these two diverging trends, the ratio of urine Ca/P, could have more discriminatory power in the separation of TPP and non-TPP. The urine Ca/P cutoff value of 1.7 mg/mg (1.4 mmol/mmol) had the optimal sensitivity (100%) and specificity (96%) for a diagnosis of TPP.
The TTKG is a simple and reliable test to evaluate the renal K ϩ excretory process (11, 12) . The normal renal response when hypokalemia is due to nonrenal causes is a TTKG Ͻ3, whereas a TTKG Ͼ3 usually reflects increased renal K ϩ excretion. Our TPP patients had appropriately low TTKG Ͻ3, indicative of their hypokalemia due to a transcellular shift of K ϩ . However, low TTKG was also found in patients with non-TPP due to SPP and gastrointestinal K ϩ loss, causing an appreciable overlap between the two groups.
Early diagnosis of TPP can aid in its management. KCl and/or phosphate supplementations can be administered to hasten strength recovery and prevent fatal arrhythmias or respiratory insufficiency during acute attacks (32) . Because hypokalemia and hypophosphatemia are the result of an intracellular shift of K ϩ and phosphate rather than a total-body deficit of these ions, excessive KCl and phosphate administration may lead to rebound hyperkalemia and hyperphosphatemia in these patients (21, 33) . It has been reported that rebound hyperkalemia (Ͼ5.0 mmol/L) occurs in 40 -70% of TPP patients treated with KCl administration (21, 32) . Because hyperadrenergic activity and hyperinsulinemia are implicated in the pathogenesis of TPP, a nonselective ␤-blocker that suppresses adrenergic activity and inhibits insulin secretion not only rapidly reverses an acute episode of TPP without the development of rebound hyperkalemia and hyperphosphatemia (34 -37) but also prevents future paralytic attacks (23, 38) . The correlation between changes in serum K ϩ level (␤ 2 effect) and heart rate (␤ 1 effect) after administration of nonselective ␤-blockers suggests that the heart rate response to nonselective ␤-blockers can be used to predict response of TPP. Hence, it is very important to differentiate TPP from non-TPP to prevent overly aggressive treatment with KCl and/or phosphate. The definitive cure for TPP is to achieve a euthyroid state by medical, surgical, or radioactive iodine therapy.
There are some limitations to this study. First, we did not control dietary factors, which can influence urine calcium and phosphate excretion. However, it may be impossible to control dietary factors in patients who unexpectedly visit EDs for severe hypokalemia with paralysis. Second, we only had a relatively small number of patients with non-TPP due to low urine K ϩ excretion; more cases are needed to validate the diagnostic value of the urine Ca/P ratio to differentiate TPP from these specific non-TPP subgroups. Third, rhabdomyolysis caused by severe hypokalemia may change serum calcium and phosphate concentrations and their urine excretion rates in this study. However, the degree of rhabdomyolysis is very mild in both TPP and non-TPP. Fourth, a high urine Ca/P ratio accompanied by a low urine K ϩ excretion, a unique finding for the diagnosis of TPP, cannot be used as the sole determining factor in developing treatment plans. The presence of tachycardia and/or systolic hypertension should influence the decision to use nonselective ␤ blockers rather than potassium and phosphate supplementation.
CONCLUSIONS
Before the present study, a careful clinical examination tempered by determination of blood and urine electrolytes and acid-base status and an electrocardiogram were the only ways to differentiate TPP from non-TPP in the ED. We now add an even more discriminating index, the urine Ca/P ratio. Urine Ca/P ratio Ͼ1.7 (mg/mg) is a distinct feature suggesting a diagnosis of TPP. Early recognition of TPP will lead to more appropriate management of this potentially fatal but readily treatable disorder, while reducing the risk of iatrogenic morbidity from overaggressive administration of KCl and/or phosphate.
